Navigation Links
Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan
Date:9/6/2010

immunotherapy tablets. In 2009, Stallergenes had a turnover of 193 million euros and more than 500,000 patients were treated with Stallergenes' immunotherapy products.

Euronext Paris (Compartment B) SBF 120. ISIN code: FR0000065674 Reuters code: GEN.PA Bloomberg code: GEN.FP Additional information is available at http://www.stallergenes.com

---------------------------------

[1] Sakurai Y, Nakamura K, Teruya K, Shimada N, Umeda T, Tanaka H, Yoshizawa N. Prevalence and risk factors of allergic rhinitis and cedar pollinosis among Japanese men. Prev Med. 1998 Jul-Aug;27(4):617-22.

[2] Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004 May;59 (5):469-78.


'/>"/>
SOURCE Stallergenes
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. STALLERGENES : Sales Guidance Exceeded : EUR193 Million, up 13%
2. STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe
3. STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial
4. STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
5. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
6. Stallergenes : Investor Meeting: Webcast is Available
7. STALLERGENES: 2008: Strong Performance
8. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
9. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
10. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
11. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
(Date:9/17/2014)... Beckman Coulter , a global leader in ... its agreement with Personify for an additional ... will continue to streamline the Beckman Coulter talent acquisition ... time-to-fill, time-to-source and a deep reduction to cost-per-hire. , ... based on the success of our partnership over the ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... 2014 The Pistoia Alliance, a ... the barriers to innovation in life sciences R&D ... Carmen Nitsche as Executive Director Business Development North ... global reach. , Carmen joins the Pistoia Alliance ... Development. At Accelrys, she managed various life sciences ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
(Date:9/17/2014)... After decades of decline, grasses have returned to ... eye, the marsh in those places seems healthy again, ... service of the marsh coastal protection remains ... ecosystem function hasn,t come back," said ecologist Mark Bertness, ... the study in the journal Biological Conservation . ...
(Date:9/17/2014)... significantly faster since the 1960s. The typical development phases ... have accelerated -- by as much as 70 percent. ... by scientists from Technische Universitt Mnchen based on long-term ... observed since 1870. Their findings were published recently in ... dieback" was a hot topic, with the very survival ...
(Date:9/17/2014)... crime unit designed to fight food fraud in ... being passed off as beef scientists from Germany ... describe their approach, which represents a vast improvement over ... Food Chemistry . , Hans-Ulrich Humpf and colleagues note ... But they also say that adding, for example, horse ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... MADISON, WI, OCTOBER 12, 2009 Areas of ... and recreational (not grazing) purposes, i.e. "urban grasslands" are ... are over 150,000 km2of urban grasslands in the U.S. ... about nutrient runoff to streams, lakes, and estuaries and ...
... by a research group at the Sahlgrenska Academy at the ... of glandular cancer usually in the head and neck and ... to quicker and better diagnosis and more effective treatment. ... Proceedings of the National Academy of Sciences (PNAS). ...
... graphene more useful in electronics applications, Kansas State University ... graphene. Vikas Berry is a K-State assistant professor ... material only a single atom thick and discovered just ... thus controlling its electronics properties -- Berry and Kabeer ...
Cached Biology News:Nitrogen mysteries in urban grasslands 2Nitrogen mysteries in urban grasslands 3New cancer gene discovered 224-carat gold 'snowflakes' improve graphene's electrical properties 2
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: